Myelitis as a side effect of tofersen therapy in SOD1-associated ALS
Authors:
Open Access
- 9 December 2023
- journal article
- letter
- Published by Springer Nature in Journal of Neurology
- Vol. 271 (4) , 2114-2118
Abstract
No abstract availableFunding Information
- Universitätsklinik München
This publication has 12 references indexed in Scilit:
- Trial of Antisense Oligonucleotide Tofersen for SOD1 ALSNew England Journal of Medicine, 2022
- The incidence of hydrocephalus among patients with and without spinal muscular atrophy (SMA): Results from a US electronic health records studyOrphanet Journal of Rare Diseases, 2021
- Hydrocephalus Complicating Intrathecal Antisense Oligonucleotide Therapy for Huntington's DiseaseMovement Disorders, 2020
- Pattern of paresis in ALS is consistent with the physiology of the corticomotoneuronal projections to different muscle groupsJournal of Neurology, Neurosurgery & Psychiatry, 2020
- Genetic epidemiology of amyotrophic lateral sclerosis: a systematic review and meta-analysisJournal of Neurology, Neurosurgery & Psychiatry, 2017
- Neurofilaments in the diagnosis of motoneuron diseases: a prospective study on 455 patientsJournal of Neurology, Neurosurgery & Psychiatry, 2015
- Rate of familial amyotrophic lateral sclerosis: a systematic review and meta-analysisJournal of Neurology, Neurosurgery & Psychiatry, 2010
- ALS motor phenotype heterogeneity, focality, and spreadNeurology, 2009
- The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory functionJournal of the Neurological Sciences, 1999
- Interobserver agreement in the assessment of muscle strength and functional abilities in Guillain‐Barré syndromeMuscle & Nerve, 1991